Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: Effects of combining beneficial single mutations

Biochemical Pharmacology

Volumn 79, Issue 2, 2010, Pages 102-111

  Jaberipour, Mansooreh ^a   Vass, Simon O ^a   Guise, Christopher P ^a   Grove, Jane I ^a   Knox, Richard J ^b   Hu, Longqin ^c   Hyde, Eva I ^a   Searle, Peter F ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b Morvus Technology Ltd   (United Kingdom)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

Cancer gene therapy; CB1954 (5 (aziridin 1 yl 2,4 dinitrobenzamide); Nitroreductase; Prodrugs; Virus directed enzyme prodrug therapy (VDEPT)

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ADENOVIRUS VECTOR; AMINO ACID; ANTINEOPLASTIC AGENT; LH 7; MUTANT PROTEIN; NITROREDUCTASE; PRODRUG; SN 23862; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CONTROLLED STUDY; DRUG ACTIVATION; DRUG SCREENING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ENGINEERING; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE MUTATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; DNA PRIMERS; HUMANS; MICE; MUTATION; NITROREDUCTASES; PRODRUGS;

EID: 71749118032     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.07.025     Document Type: Article

References (53)

1. Pandha H.S., Martin L.A., Rigg A., Hurst H.C., Stamp G.W., Sikora K., et al. Genetic prodrug activation therapy for breast cancer: a phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol 17 (1999) 2180-2189
2. Freytag S.O., Stricker H., Pegg J., Paielli D., Pradhan D.G., Peabody J., et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 63 (2003) 7497-7506
3. Palmer D.H., Mautner V., Mirza D., Oliff S., Gerritsen W., Van Der Sijp J.R., et al. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol 22 (2004) 1546-1552
4. Braybrooke J.P., Slade A., Deplanque G., Harrop R., Madhusudan S., Forster M.D., et al. Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. Clin Cancer Res 11 (2005) 1512-1520
5. Dachs G.U., Tupper J., and Tozer G.M. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 16 (2005) 349-359
6. Tai C.K., Wang W.J., Chen T.C., and Kasahara N. Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol Ther 12 (2005) 842-851
7. Niculescu-Duvaz I., and Springer C.J. Introduction to the background, principles, and state of the art in suicide gene therapy. Mol Biotechnol 30 (2005) 71-88
8. Young L.S., Searle P.F., Onion D., and Mautner V. Viral gene therapy strategies: from basic science to clinical application. J Pathol 208 (2006) 299-318
9. McNeish I.A., Searle P.F., Young L.S., and Kerr D.J. Gene directed enzyme prodrug therapy for cancer. Adv Drug Deliv Rev 26 (1997) 173-184
10. Moolten F.L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes - paradigm for a prospective cancer control strategy. Cancer Res 46 (1986) 5276-5281
11. Mullen C.A., Kilstrup M., and Blaese R.M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA 89 (1992) 33-37
12. McNeish I.A., Green N.K., Gilligan M.G., Ford M.J., Mautner V., Young L.S., et al. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Ther 5 (1998) 1061-1069
13. Grove J.I., Searle P.F., Weedon S.J., Green N.K., McNeish I.A., and Kerr D.J. Virus directed enzyme prodrug therapy using CB1954. Anti-Cancer Drug Des 14 (1999) 461-472
14. Weedon S.J., Green N.K., McNeish I.A., Gilligan M.G., Mautner V., Wrighton C.J., et al. Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase. Int J Cancer 86 (2000) 848-854
15. Djeha A.H., Thomson T.A., Leung H., Searle P.F., Young L.S., Kerr D.J., et al. Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors. Mol Ther 3 (2001) 233-240
16. Roberts J.J., Friedlos F., and Knox R.J. CB1954 (2,4-dinitro-5-aziridinyl benzamide) becomes an interstrand crosslinking agent in Walker tumour cells. Biochem Biophys Res Commun 140 (1986) 1073-1078
17. Connors T.A. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther 2 (1995) 702-709
18. Bridgewater J.A., Springer C.J., Knox R.J., Minton N.P., Michael N.P., and Collins M.K. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur J Cancer 31A (1995) 2362-2370
19. de Poorter J.J., Tolboom T.C., Rabelink M.J., Pieterman E., Hoeben R.C., Nelissen R.G., et al. Towards gene therapy in prosthesis loosening: efficient killing of interface cells by gene-directed enzyme prodrug therapy with nitroreductase and the prodrug CB1954. J Gene Med 7 (2005) 1421-1428
20. Drabek D., Guy J., Craig R., and Grosveld F. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954. Gene Ther 4 (1997) 93-100
21. Gusterson B.A., Cui W., and Clark A.J. Development of novel selective cell ablation in the mammary gland and brain to study cell-cell interactions and chemoprevention. Recent Results Cancer Res 163 (2003) 31-45 discussion 264-6
22. Kwak S.P., Malberg J.E., Howland D.S., Cheng K.Y., Su J., She Y., et al. Ablation of central nervous system progenitor cells in transgenic rats using bacterial nitroreductase system. J Neurosci Res 85 (2007) 1183-1193
23. Pisharath H., and Parsons M.J. Nitroreductase-mediated cell ablation in transgenic zebrafish embryos. Methods Mol Biol 546 (2009) 133-143
24. Smits A.M., van den Hengel L.G., van den Brink S., Metz C.H., Doevendans P.A., and Goumans M.J. A new in vitro model for stem cell differentiation and interaction. Stem Cell Res 2 (2009) 108-112
25. Ram Z., Culver K.W., Oshiro E.M., Viola J.J., DeVroom H.L., Otto E., et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 3 (1997) 1354-1361
26. Herman J.R., Adler H.L., Aguilar-Cordova E., Rojas-Martinez A., Woo S., Timme T.L., et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 10 (1999) 1239-1249
27. Freytag S.O., Khil M., Stricker H., Peabody J., Menon M., DePeralta-Venturina M., et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 62 (2002) 4968-4976
28. Patel P., Young J.G., Mautner V., Ashdown D., Bonney S., Pineda R.G., et al. A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954. Mol Ther 17 (2009) 1292-1299
29. Green N.K., McNeish I.A., Doshi R., Searle P.F., Kerr D.J., and Young L.S. Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronic adenovirus vector. Int J Cancer 104 (2003) 104-112
30. Chen M.J., Green N.K., Reynolds G.M., Flavell J.R., Mautner V., Kerr D.J., et al. Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector. Gene Ther 11 (2004) 1126-1136
31. Lukashev A.N., Fuerer C., Chen M.J., Searle P., and Iggo R. Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954. Hum Gene Ther 16 (2005) 1473-1483
32. Grove J.I., Lovering A.L., Guise C., Race P.R., Wrighton C.J., White S.A., et al. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954. Cancer Res 63 (2003) 5532-5537
33. Guise C.P., Grove J.I., Hyde E.I., and Searle P.F. Direct positive selection for improved nitroreductase variants using SOS triggering of bacteriophage lambda lytic cycle. Gene Ther 14 (2007) 690-698
34. Anlezark G.M., Melton R.G., Sherwood R.F., Coles B., Friedlos F., and Knox R.J. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)-I. Purification and properties of a nitroreductase enzyme from Escherichia coli-a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem Pharmacol 44 (1992) 2289-2295
35. Jarrom D., Jaberipour M., Guise C.P., Daff S., White S.A., Searle P.F., et al. Steady-state and stopped-flow kinetic studies of three Escherichia coli nfsB mutants with enhanced activity for the prodrug CB1954. Biochemistry. 48 (2009) 7665-7672
36. Workman P., White R.A.S., and Talbot K. CB1954 revisited. I. Disposition kinetics and metabolism. Cancer Chemother Pharmacol 16 (1986) 1-8
37. Chung-Faye G., Palmer D., Anderson D., Clark J., Downes M., Baddeley J., et al. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin Cancer Res 7 (2001) 2662-2668
38. Lovering A.L., Hyde E.I., Searle P.F., and White S.A. The structure of Escherichia coli nitroreductase complexed with nicotinic acid: three crystal forms at 1.7 Å, 1.8 Å and 2.4 Å resolution. J Mol Biol 309 (2001) 203-213
39. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
40. Graham F.L., Smiley J., Russell W.C., and Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36 (1977) 59-72
41. Fallaux F.J., Kranenburg O., Cramer S.J., Houweling A., van Ormondt H., Hoeben R.C., et al. Characterization of 911: a new helper cell line for the titration and propagation of early-region-1-deleted adenoviral vectors. Hum Gene Ther 7 (1996) 215-222
42. Jiang Y., Han J., Yu C., Vass S.O., Searle P.F., Browne P., et al. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation. J Med Chem 49 (2006) 4333-4343
43. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
44. Green N.K., Youngs D.J., Neoptolemos J.P., Friedlos F., Knox R.J., Springer C.J., et al. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther 4 (1997) 229-238
45. Cosset F.L., Takeuchi Y., Battini J.L., Weiss R.A., and Collins M.K. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 69 (1995) 7430-7436
46. Parkinson G.N., Skelly J.V., and Neidle S. Crystal structure of FMN-dependent nitroreductase from Escherichia coli B: A prodrug-activating Enzyme. J Med Chem 43 (2000) 3624-3631
47. Anlezark G.M., Melton R.G., Sherwood R.F., Wilson W.R., Denny W.A., Palmer B.D., et al. Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. Biochem Pharmacol 50 (1995) 609-618
48. Yoshikuni Y., Ferrin T.E., and Keasling J.D. Designed divergent evolution of enzyme function. Nature 440 (2006) 1078-1082
49. Wilson W.R., Pullen S.M., Hogg A., Helsby N.A., Hicks K.O., and Denny W.A. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Cancer Res 62 (2002) 1425-1432
50. Helsby N.A., Ferry D.M., Patterson A.V., Pullen S.M., and Wilson W.R. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT. Br J Cancer 90 (2004) 1084-1092
51. Singleton D.C., Li D., Bai S.Y., Syddall S.P., Smaill J.B., Shen Y., et al. The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR). Cancer Gene Ther 14 (2007) 953-967
52. Hu L., Yu C., Jiang Y., Han J., Li Z., Browne P., et al. Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy. J Med Chem 46 (2003) 4818-4821
53. Kraulis P.J. MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr 24 (1991) 946-950